Viewing nowMemantine Tablets 10 mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

MFDS item code 200500430 · Notified 2005.06.30 · Insurance code 642900500
Treatment of moderate to severe Alzheimer's disease
This medication is used for the treatment of moderate to severe Alzheimer's disease. It helps alleviate the patient's cognitive decline and maintains the ability for daily activities.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's dementia, and only if a caregiver can periodically confirm that the patient is taking the medication. Diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medicine and the patient's tolerability of treatment should be reassessed periodically. This medicine may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Day 1–7): Administer 5mg once daily for 7 days. Week 2 (Day 8–14): Administer 10mg daily (5mg twice daily) for 7 days. Week 3 (Day 15–21): Administer 15mg daily (10mg in the morning and 5mg in the evening) for 7 days. From Week 4 onward: Administer 20mg daily (10mg twice daily). Maintenance dose: The recommended maintenance dose is 20mg daily (10mg twice daily). 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years and above is 20mg daily (10mg twice daily). 3. Patients with renal impairment: No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg daily according to the standard dose-escalation schedule. In patients with severe renal impairment (creatinine clearance 5-30 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication should not be used in patients who are allergic to any component of this medication or in patients with severe liver or kidney dysfunction. Care should be taken when using this medication in patients with epilepsy, those who have experienced seizures, or those who are prone to seizures. Additionally, co-administration with NMDA antagonists such as amantadine, ketamine, or dextromethorphan may increase side effects, and should be avoided. Patients with changes in urine acidity (pH) or dietary habits that may increase urine acidity should be monitored carefully. There is insufficient clinical data in patients with myocardial infarction, heart failure, or uncontrolled hypertension, so administration should be cautious. While taking this medication, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur. Mental confusion, hallucinations, and psychotic symptoms may also occur rarely, so caution is required. This medication may interact with other substances, so it is important to consult with a doctor or pharmacist if taken alongside antipsychotic medications, muscle relaxants, anticoagulants, etc. Women who are pregnant or may become pregnant should carefully consider the risks and benefits of using this medication, and discontinuation of breastfeeding is recommended while using it. Safety and efficacy in children and adolescents under 18 years of age have not been established. In case of overdose, serious symptoms such as coma, hallucinations, and seizures may occur, so immediate medical attention is necessary. This medication can affect the central nervous system, so care should be taken when driving or operating machinery. Finally, this medication should be kept out of reach of children and should not be transferred to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that is well-ventilated and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way maintains the drug's effectiveness and prevents degradation.
White, rectangular film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.